The Clinical and Computed Tomography Findings of Patients with COVID-19
1Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
2Department of Radiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
3Department of General Surgery, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
DOI: 10.22514/sv.2020.16.0023 Vol.16,Issue 1,June 2020 pp.173-178
Published: 30 June 2020
Objective: To evaluate the demographic, clinical data and, computed tomography findings of patients diagnosed COVID-19. Methods: Patients who had COVID 19 suspicion in the emergency department of the university hospital in Istanbul, Turkey, between March 20, 2020, and April 1, 2020, were scanned. Demographic, characteristics, and computed tomography findings of patients with positive RT-PCR test results were analyzed. Results: The mean age of patients was 51.27 (6.45) years, and 72.5% were male. The median admission period of patients was 4 (1 - 10) days, and the mean length of hospital stay was 10.49 (6.6) days. The mean CT result time was 33.24 (11.56) minutes, and RT-PCR was 35.53 (14.36) hours. The most common complaint was a fever. Furthermore, shortness of breath and dry cough was other evident complaints. Only 7.8% of patients were asymptomatic. In 84.3% and 80.5% of patients had increased C-reactive protein levels and increased ferritin levels, while in 41.2% of patients had decreased lymphocyte count. Bilateral lung involvement, multifocal localized lung lesions, peripheral and central distribution of lesions were detected in most patients. Lesions were located at the posterior lung in more than half of the patients. The rate of involvement of the lower lobes was higher. Some 84.5% of the patients had two or more lobe involvements. Ground glass density (94.1%), consolidation (80.4%), pleural thickening (64.7%), crazy paving pattern (52.9%), vascular enlargement (47.1%), halo sign (43.1%), and air bronchogram (33.3%) were the most seen lesions. Conclusion: Computed tomography could be helpful in coordination with the clinical and laboratory parameters for early decision and isolation of patients with suspected COVID-19 until RT-PCR test results obtained.
COVID-19, SARS-CoV-2, Coronavirus, Computed tomography
Afsin Ipekci,Yonca Senem Akdeniz,Onur Tutar,Sabri Sirolu,Osman Simsek,Seda Özkan. The Clinical and Computed Tomography Findings of Patients with COVID-19. Signa Vitae. 2020. 16(1);173-178.
 Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
 World Health Organization (2020) Coronavirus disease 2019 (COVID-19) situation report–39. World Health Organization,Geneva. 2020. accessable on: https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 20200228-sitrep-39-covid-19.pdf?sfvrsn=5bbf3e7d_2.
 John Hopkins University Coronavius Research Center. 2020. access-able on: https://coronavirus.jhu.edu/map.html.
 T.C Sağlık Bakanlığı Türkiye’de güncel durum. 2020. accessable on: https://covid19.saglik.gov.tr/.
 Xie X, Zhong Z, Zhao W, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020.
 Huang P, Liu T, Huang L, et al. Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. Radiology. 2020.
 Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology. 2020.
 Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020;26:200642.
 Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425-434.
 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
 Karcıoğlu Ö. What is Coronaviruses, and How Can We Protect Ourselves? Phnx Med J. 2020;2:66-71.
 Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47:1275-1280.
 Cheng Z, Qin L, Cao Q, et al. Quantitative computed tomography of the coronavirus disease 2019 (COVID-19) pneumonia. Radiology of Infectious Diseases. 2020.
 Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding ofn2019-nCoV infections. 2020.
 Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020.
 Lei J, Li J, Li X, et al. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology. 2020;295:18.
 Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020.
 Zhao W, Zhong Z, Xie X, et al. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol. 2020;214:1072-1077.
 Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020.
 Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Invest Radiol. 2020;55:327-331.
Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.
Editorial review: 1 - 2 days
Peer review: 1 - 2 months
Ahead of Print: within 2 months after being accepted
Notes: Your information is kept confide-ntial throughout the review process.